Cardiovascular adverse events associated with the 4 types of COVID-19 vaccines
|
Reviewed by Nhi Le, B.A
|
Posted on August 24th, 2022
|
According to the VigiBase pharmacovigilance database created by the World Health Organization, myocardial infarction, pulmonary embolism, and stroke are frequently reported after COVID-19 vaccination. Using data from the French National Health Data System, a recent publication on the Annals of Internal Medicine reports the association between COVID-19 vaccination and severe cardiovascular events
The study used data from 46.5 million adults between the age of 18 and 74 years old to assess the short-term risk of cardiovascular events following immunization with the COVID-19 vaccines manufactured by Pfizer–BioNTech, Moderna, Oxford-AstraZeneca, and Janssen. The study reports that the Pfizer-BioNTech and Moderna formulation is not associated with any cardiovascular events; thus, this adds into the current evidence proving the safety profile of the mRNA COVID-19 vaccines. However, the risk of myocardial infarction and pulmonary embolism is slightly elevated for those who received adenoviral-based vaccines such as Oxford-AstraZeneca and Janssen. The risk of myocardial infarction and pulmonary embolism in those receiving the Oxford-AstraZeneca vaccine is 1.29 times and 1.41 times higher, respectively. The Janssen vaccine is only associated with myocardial infarction with an elevated risk of 1.75 times.
More research is needed to define the causality relationship, potential mechanism of action needed for a more solid recommendation of usage and contraindication for the 2 adenovirus vector COVID-19 vaccine.
The study used data from 46.5 million adults between the age of 18 and 74 years old to assess the short-term risk of cardiovascular events following immunization with the COVID-19 vaccines manufactured by Pfizer–BioNTech, Moderna, Oxford-AstraZeneca, and Janssen. The study reports that the Pfizer-BioNTech and Moderna formulation is not associated with any cardiovascular events; thus, this adds into the current evidence proving the safety profile of the mRNA COVID-19 vaccines. However, the risk of myocardial infarction and pulmonary embolism is slightly elevated for those who received adenoviral-based vaccines such as Oxford-AstraZeneca and Janssen. The risk of myocardial infarction and pulmonary embolism in those receiving the Oxford-AstraZeneca vaccine is 1.29 times and 1.41 times higher, respectively. The Janssen vaccine is only associated with myocardial infarction with an elevated risk of 1.75 times.
More research is needed to define the causality relationship, potential mechanism of action needed for a more solid recommendation of usage and contraindication for the 2 adenovirus vector COVID-19 vaccine.